May 14, 2026 07:15AM
May 11, 2026 08:05AM
May 5, 2026 07:10AM
May 5, 2026 07:10AM
May 5, 2026 07:03AM
May 5, 2026 07:00AM
Apr 14, 2026 08:35AM Cellectar enrolls first patient in breast cancer drug trial
Apr 14, 2026 08:35AM
Sep 3, 2025 08:05AM
Aug 14, 2025 07:19AM
Mar 11, 2025 08:05AM
Feb 5, 2025 08:05AM
Jan 7, 2019 08:30AM
Jan 3, 2019 08:30AM Cellectar Biosciences to Present at the Biotech Showcase
Dec 11, 2018 08:32AM
Dec 11, 2018 08:30AM
Dec 4, 2018 08:30AM
Nov 13, 2018 08:30AM
Nov 12, 2018 08:30AM
Oct 2, 2018 08:04AM
Oct 2, 2018 08:00AM Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma
Sep 25, 2018 08:39AM
Sep 25, 2018 08:30AM
Sep 24, 2018 08:00AM
Sep 17, 2018 08:34AM
Sep 17, 2018 08:30AM
Aug 20, 2018 08:30AM
Aug 13, 2018 08:00AM Cellectar’s CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing’s Sarcoma
Aug 10, 2018 08:00AM
Aug 1, 2018 08:30AM
Jul 31, 2018 04:05PM
Jul 27, 2018 08:30AM
Jul 18, 2018 08:00AM
Jul 17, 2018 08:00AM
Jul 13, 2018 04:05PM Cellectar Announces 1-for-10 Reverse Stock Split
Jul 9, 2018 08:08AM
Jul 9, 2018 08:00AM
Jun 28, 2018 08:00AM
Jun 7, 2018 08:33AM
Jun 7, 2018 08:30AM
Jun 6, 2018 08:02AM
Jun 6, 2018 08:00AM FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Rhabdomyosarcoma
May 11, 2018 08:00AM
May 9, 2018 02:29PM
May 9, 2018 02:28PM
May 2, 2018 08:10AM
May 2, 2018 08:00AM
Apr 17, 2018 08:02AM
Apr 17, 2018 08:00AM Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating Efficacy of Fractionated Injections of CLR 131 in Multiple Myeloma
Apr 16, 2018 08:05AM

322,950 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All